Difference between revisions of "Talk:SUIT-016"
From Bioblast
(Created page with "::: '''SUIT states:''' 1-2OctM(LP);3GMOct;4GMSOct;5-7S(PLEc);8ROX {| class="wikitable" border="1" |- ! Step ! Respiratory state ! Pathway control ! Pathwa...") Β |
Beno Marija (talk | contribs) Β |
||
(One intermediate revision by one other user not shown) | |||
Line 21: | Line 21: | ||
| [[F]] | | [[F]] | ||
| CETF | | CETF | ||
| [[OXPHOS coupling efficiency]] in state F. | | [[OXPHOS-coupling efficiency]] in state F. | ||
|- | |- | ||
Line 42: | Line 42: | ||
| [[S]] | | [[S]] | ||
| CII | | CII | ||
| The ''P/E'' ratio is not obtained in the FNS state, with preference given to the next steps for OXPHOS coupling efficiency. A succinate concentration of >10 mM may be required for saturating S<sub>''P''</sub> capacity. | | The ''P/E'' ratio is not obtained in the FNS state, with preference given to the next steps for OXPHOS-coupling efficiency. A succinate concentration of >10 mM may be required for saturating S<sub>''P''</sub> capacity. | ||
|- | |- | ||
Line 49: | Line 49: | ||
| [[S]] | | [[S]] | ||
| CII | | CII | ||
| [[OXPHOS coupling efficiency]] in state S, comparable to state F. | | [[OXPHOS-coupling efficiency]] in state S, comparable to state F. | ||
|- | |- |
Latest revision as of 14:39, 3 June 2020
Step | Respiratory state | Pathway control | Pathway to Q | Comment |
---|---|---|---|---|
1OctM | OctM(L) | F | CETF | |
2D | OctM(P) | F | CETF | OXPHOS-coupling efficiency in state F. |
3G | GMOct(P) | FN | FAO&CI | F/N ratio or (N-F)/N flux control factor of OXPHOS capacity. |
4S | GMSOct(P) | FNS | FAO&CI&II | Additive effect of the NS pathway combination, compared to the sum of N+S pathway fluxes measured separately, in the OXPHOS state and the presence of F. |
5Rot | S(P) | S | CII | The P/E ratio is not obtained in the FNS state, with preference given to the next steps for OXPHOS-coupling efficiency. A succinate concentration of >10 mM may be required for saturating SP capacity. |
6Omy | S(L) | S | CII | OXPHOS-coupling efficiency in state S, comparable to state F. |
7U | S(E) | S | CII | The complete ET capacity in state S may not be obtained after oligomycin. If apparent P/E>1.0, this is corrected to 1.0. |
7c | S(E) | S | CII | If cytochrome c control factors = 0.0, the cytochrome c test conducted at this very late ET-pathway state provides an additional indication of stability of the mt-preparation during the experimental assay. Application of the cytochrome c test earlier in the protocol (SUIT-011: 1GM;2D;2c;3S; ..) is preferable, if cytochrome c control factors > 0.0 may be observed occasionally or regulary. If such cytochrome c effects are not exclusion criteria, then OXPHOS states with all substrate combinations can be compared in the presence of cytochrome c. |
8Ama | ROX | ROX | ROX may be lower in substrate states earlier in the SUIT protocol. Therefore, this ROX measurement is frequently taken as a methodological control rather than as the basis of ROX correction of mitochondrial respiration (mt). |